Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh

Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh

KKRX:950200
2,610.00
KRW
-40.00
(-1.51%)
-91.27EPS
26.36P/E
53.86BMarket Cap
Psomagen Inc Shs Korean Depositary Receipt Repr 1 Sh
KRX:950200
(Korea Stock Exchange)

Recent

price

2,610.00

P/E

ratio

26.36

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,036.34
1,867.89
1,246.79
1,481.92
2,151.62
1,670.83
2,222.86
3,095.65
2,899.16
Revenue per Share
-128.13
-2,145
-1,416
-366
-52
-222
-286
-156
106.22
Basic EPS, GAAP
166.58
-1,041.5
-417.9
-436.56
-194.92
-205.7
-83.28
-3.52
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-181.66
-998.26
1,967.73
1,784.59
1,858.02
1,674.99
1,599.27
1,418.88
1,661.12
Book Value per Share
-184.68
-1,428.98
1,529.71
1,277.22
1,362.47
1,231.69
1,234.15
1,091.12
1,382.8
Tangible Book Value per Share
20
11
15
19
20
19
20
19
20
Basic Weighted Avg Shares
20,876
20,087
19,006
28,592
43,374
32,275
43,664
59,192
57,289
Sales/Revenue/Turnover
-14.57
-24.18
-54.05
-27.05
-3.4
-11.01
-11.98
-3.81
-1.43
Operating Margin (%)
3,247
3,791
3,746
3,415
3,847
3,975
5,134
5,187
- -
Depreciation Expense
-2,581
-23,067
-21,585
-7,061
-1,048
-4,288
-5,618
-2,983
2,099
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-12.36
-114.84
-113.57
-24.7
-2.42
-13.29
-12.87
-5.04
3.66
Profit Margin (%)
4,112
-32,779
24,615
18,635
18,659
13,868
10,260
10,456
18,251
Working Capital
14,554
3,403
3,821
4,667
3,826
3,483
8,470
8,487
8,171
LT Debt
-3,438
-18,894
37,242
34,146
35,683
32,247
30,287
25,715
31,953
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-19.78
-3
-12.63
-17.84
-10.28
7.25
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,709
6,470
1,674
LT Borrowings
- -
- -
- -
LT Finance Leases
8,487
8,583
8,171
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
74,636
68,288
53,861

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
25,948
29,332
30,832
Cash, Cash Equivalents & STI
12,081
14,168
16,396
Accounts Receivable, Net
7,220
7,379
6,805
Inventories
5,416
6,148
6,502
Total Current Liabilities
15,492
18,374
12,581
Payables & Accruals
- -
- -
- -
ST Debt
4,709
6,470
1,674
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-6.93%
-15.1%
Free Cash Flow
- -
-34.95%
-95.89%
Net Income, GAAP
- -
28.15%
-46.9%
Sales/Revenue/Turnover
- -
29.48%
35.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,360
8,536
11,733
13,841
43,664
2025
11,318
15,909
15,391
17,054
59,192
2026
12,828
12,016
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-93
-81
-81
-63.45
-286
2025
-87
-57
-14
-0.15
-156
2026
-18.57
148
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Psomagen, Inc. is a genomics and multi-omics contract research organization that provides comprehensive genetic sequencing, bioinformatics, and clinical diagnostic services to academic institutions, biotechnology and pharmaceutical companies, healthcare organizations, and government research agencies. Founded in 2004 as a United States subsidiary of South Korea-based Macrogen Inc. and formerly known as Macrogen Corp. USA prior to its corporate rebranding and subsequent public listing on the KOSDAQ via Korean Depositary Receipts, the company is headquartered in Rockville, Maryland, and maintains College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory facilities serving clients across North America and international markets. The company operates across genomic research, clinical diagnostics, and consumer health segments, delivering a systematic portfolio of laboratory and analytical offerings: Next-Generation Sequencing (NGS) services, including whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panel sequencing, transcriptomics and RNA sequencing (RNA-seq), epigenomic analysis such as ChIP-seq and Methyl-seq, and metagenomic microbiome sequencing; Capillary Electrophoresis Sequencing (CES) and Sanger sequencing solutions, delivering standard DNA sequencing, fragment analysis, and plasmid sequencing; Single-Cell and Spatial Biology services, encompassing single-cell RNA sequencing, spatial transcriptomics, and high-resolution tissue spatial imaging; Proteomics and Multi-Omics profiling, offering high-throughput protein biomarker discovery and multiplex protein quantification assays; Clinical and Molecular Diagnostic services, comprising hereditary cancer screening, somatic oncology testing, carrier screening, and pharmacogenomics (PGx); Direct-to-Consumer (DTC) and Wellness testing kits, including gut microbiome profiling panels; and Advanced Bioinformatics services, providing tailored computational pipelines, variant annotation, statistical genomics, and secure cloud-hosted data delivery. In recent developments, Psomagen, Inc. has accelerated its expansion into spatial biology and high-throughput proteomics by deploying advanced analytical platforms, including partnerships and service validations with Olink Proteomics for large-scale protein biomarker discovery and 10x Genomics for single-cell and spatial tissue profiling. The company has diversified its sequencing instrumentation through the operational adoption of next-generation sequencing platforms such as Element Biosciences' AVITI system and Pacific Biosciences long-read sequencing technology, optimizing operational efficiency, assay accuracy, and cost-per-sample economics. Furthermore, Psomagen has strengthened its public-sector and institutional engagement through research service contracts with biomedical organizations, including the National Institutes of Health (NIH), while continuing to upgrade its Rockville facilities with automated sample preparation workflows and expanded commercial offerings in clinical microbiome and multi-omics testing.